14.49  0 (0%)		04-27 16:00
Open: 14.49 High: 14.49 Volume: 0		Pre. Close: 14.49 Low: 14.49 Market Cap: 4,550(M)

Short term
Mid term
Targets	6-month :	16.93	1-year :	19.78
Resists	First :	14.5	Second :	16.93
Pivot price	14.46
Supports	First :	14.43	Second :	14.39
MAs	MA(5) :	14.47	MA(20) :	14.45
	MA(100) :	13.81	MA(250) :	9.93
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	75.2	D(3) :	68.6
RSI	RSI(14): 72.1
52-week	High :	14.5	Low :	5.51

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ FOLD ] has closed Bollinger Bands are 95.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 72 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	14.51 - 14.58	14.58 - 14.65
Low:	14.3 - 14.39	14.39 - 14.47
Close:	14.35 - 14.49	14.49 - 14.62

Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.

Wed, 29 Apr 2026
BioMarin Closes Amicus Deal As FOLD Delists And Indices Adjust - simplywall.st

Mon, 27 Apr 2026
BioMarin Completes Acquisition of Amicus Therapeutics - PR Newswire

Sat, 25 Apr 2026
CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD) - The Motley Fool

Fri, 06 Mar 2026
How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin’s Rare Disease Portfolio - Yahoo Finance

Tue, 03 Mar 2026
Amicus Therapeutics shareholders approve acquisition by BioMarin Pharmaceutical - Investing.com

Fri, 20 Feb 2026
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	314 (M)
Shares Float	311 (M)
Held by Insiders	0.6 (%)
Held by Institutions	104.3 (%)
Shares Short	21,920 (K)
Shares Short P.Month	20,190 (K)

EPS	-0.1
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.87
Profit Margin	-4.3 %
Operating Margin	8.6 %
Return on Assets (ttm)	2.4 %
Return on Equity (ttm)	-11.6 %
Qtrly Rev. Growth	23.7 %
Gross Profit (p.s.)	1.78
Sales Per Share	2.01
EBITDA (p.s.)	0.13
Qtrly Earnings Growth	-95.5 %
Operating Cash Flow	33 (M)
Levered Free Cash Flow	48 (M)

PE Ratio	-161
PEG Ratio	0
Price to Book value	16.46
Price to Sales	7.17
Price to Cash Flow	137.25

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.